Saul Kivimae

Vice President & Head of Pharmacology Nektar Therapeutics

Seminars

Wednesday 24th March 2027
Enhancing Endogenous Treg Function to Deliver Durable Clinical Benefit in Atopic Dermatitis & Autoimmune Disease
4:00 pm
  • Exploring strategies for enhancing endogenous patient Treg numbers and activity as an alternative to understand where Treg-modulating approaches may offer clinical advantages
  • Evaluating clinical learnings from advancing Treg-enhancing therapies in atopic dermatitis and broader autoimmune disease settings to inform future development strategies
  • Comparing approaches for activating and strengthening natural Treg function to achieve durable immune regulation while addressing the challenges of chronic inflammatory disease
Saul